Literature DB >> 8630661

Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men.

M Cigolini1, G Targher, I A Bergamo Andreis, M Tonoli, G Agostino, G De Sandre.   

Abstract

The associations between abdominal visceral fat and the plasma hemostatic system were examined in 38-year-old healthy men (n=52) with a wide range of fatness and fat distribution. Plasma hemostatic factors and metabolic parameters, including glucose tolerance, were measured, and body fatness and adipose tissue distribution were assessed by using computed tomography. The men with more visceral fat (ie, higher than the median value [n=26]) had a less favorable metabolic profile than the men with less visceral fat (n=26). They also had significantly (P<.05) higher plasma fibrinogen, factor VIII clotting activity, tissue-type plasminogen activator antigen, and plasminogen activator inhibitor-1 (PAI-1) activity (19.2+/-2.4 versus 8.5+/-1.6 AU/mL, P<.001) and lower basal tissue-type plasminogen activator activity. After adjustment for plasma insulin, the men with larger abdominal visceral fat area still had significantly higher plasma PAI-1 activity, but no difference was found in any of the other hemostatic factors. In multiple linear regression analysis, abdominal visceral fat area was a positive predictor of plasma PAI-1 activity, but it failed to show any significant association with other hemostatic factors after controlling for plasma insulin. These results suggest the presence of relationships between abdominal visceral fat and several plasma hemostatic factors that are largely mediated by concomitant alterations in plasma insulin concentration. In addition, our results suggest that abdominal accumulation of visceral fat is an independent predictor of plasma PAI-1 activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630661     DOI: 10.1161/01.atv.16.3.368

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  18 in total

1.  The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49.

Authors:  Tomoko Takamiya; Takashi Kadowaki; Wahid R Zaky; Hirotsugu Ueshima; Rhobert W Evans; Tomonori Okamura; Atsunori Kashiwagi; Yasuyuki Nakamura; Yoshiyuki Kita; Russell P Tracy; Lewis H Kuller; Akira Sekikawa
Journal:  Diabetes Res Clin Pract       Date:  2005-12-01       Impact factor: 5.602

2.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

Review 3.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 4.  Fibrinolytic function and coronary risk.

Authors:  I Juhan-Vague; P Morange; M Christine Alessi
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

5.  Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters.

Authors:  Assimina Galli-Tsinopoulou; Ioannis Kyrgios; Ioanna Maggana; Eleni Z Giannopoulou; Eleni P Kotanidou; Charilaos Stylianou; Emmanouil Papadakis; Ioannis Korantzis; George Varlamis
Journal:  Eur J Pediatr       Date:  2010-12-08       Impact factor: 3.183

6.  Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology.

Authors:  L M Steffen; M Cushman; J M Peacock; S R Heckbert; D R Jacobs; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2009-01-19       Impact factor: 5.824

7.  Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation.

Authors:  Elzbieta Kozek; Barbara Katra; Maciej Malecki; Jacek Sieradzki
Journal:  Rev Diabet Stud       Date:  2004-11-10

Review 8.  Obesity and cardiovascular disease.

Authors:  Paul Poirier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2002-11       Impact factor: 5.113

Review 9.  Coagulation and fibrinolysis abnormalities in obesity.

Authors:  G De Pergola; N Pannacciulli
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

10.  Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue.

Authors:  Ivana Zagotta; Elitsa Y Dimova; Jan-Bernd Funcke; Martin Wabitsch; Thomas Kietzmann; Pamela Fischer-Posovszky
Journal:  Oxid Med Cell Longev       Date:  2013-06-02       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.